target="_new">http://www.exonhit.com), that may cause actual results, performance or
events to differ materially from those anticipated in the summary information.
In addition, ExonHit Therapeutics, its shareholders, and its affiliates,
directors, officers, advisors and employees have not verified the accuracy
of, and make no representations or warranties in relation to, statistical
data or predictions contained in this press release that were taken or
derived from third party sources or industry publications, and such
statistical data and predictions are used in this press release for
information purposes only.
Finally, this press release may be drafted in the French and English
languages. In an event of differences between the texts, the French language
version shall prevail.
'/>"/>SOURCE ExonHit Therapeutics SA Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials2.
ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood3.
ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease4.
ExonHit and bioMerieux Amend Their Strategic Partnership5.
ExonHit Builds A New Organisation6.
ExonHit Therapeutics - 2007 Financial Results7.
ExonHit Appoints a New Management Board8.
Frederic Desdouits Appointed Member of the Supervisory Board of ExonHit Therapeutics9.
ExonHit Launches Rat Genome SpliceArray(TM) Products to Expand High Resolution Gene Expression Profiling for use in Disease Modeling and Toxicogenomics10.
Loic Maurel Joins Exonhit Therapeutics to Become CEO11.
Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs